section name header

Pronunciation ⬇

pra-soo-GREL

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents

Pharmacologic Classification: thienopyridines

Indications ⬆ ⬇

BEERS REMS


Action ⬆ ⬇

  • Acts by irreversibly binding its active metabolite to the P2Y12 class of ADP receptors on platelets; inhibiting platelet activation and aggregation.
Therapeutic effects:
  • Decreased thrombotic events including cardiovascular death, nonfatal MI, and nonfatal stroke.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration (79%), then rapidly converted to an active metabolite.

Distribution: Unknown.

Protein Binding: Active metabolite: 98%.

Metabolism/Excretion: Active metabolite is metabolized to two inactive compounds; 68% excreted in the urine and 27% in feces as inactive metabolites.

Half-Life: Active metabolite: 7 hr (range 2–15 hr).

Time/Action Profile ⬆ ⬇

(effect on platelet function)

ROUTEONSETPEAKDURATION
POwithin 1 hr2 hr5–9 days‡

‡Following discontinuation.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Effient

Code ⬆

NDC Code